IgE ANTIBODIES FOR THE INHIBITION OF TUMOR METASTASIS
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsJoseph A. Mollick, Pearline Teo, Paul J. Utz
Life of this patent
Estimating the term…
Abstract
The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
Claims30
A method for reprogramming the activity of at least one host-derived, non-tumor cell located in the microenvironment of a solid tumor in a patient wherein the ability of the non-tumor cell to mediate metastases of the tumor is inhibited, comprising the step of administering an IgE antibody specific for a tumor-associated antigen, wherein the antibody forms a ternary complex within the microenvironment of the tumor, said ternary complex being comprised of the IgE antibody, the tumor-associated antigen, and a host-derived, non-tumor cell endogenous to the tumor environment wherein the antibody specifically binds to the tumor-associated antigen and an antibody receptor specific for IgE located on the surface of the host-derived non-tumor cell.
A method for inhibiting metastasis of a solid tumor in a patient, the method comprising administering to the patient, an IgE antibody capable of forming a ternary complex within the microenvironment of the tumor, said ternary complex being comprised of the IgE antibody specific for a tumor-associated antigen, the tumor-associated antigen and a host-derived non-tumor cell endogenous to the tumor microenvironment, wherein the antibody specifically binds to the tumor-associated antigen and an antibody receptor specific for IgE located on the surface of the host-derived, non-tumor cell and wherein upon the formation of the ternary complex, the ability of the non-tumor cell to mediate metastases of the tumor is inhibited.
An IgE monoclonal antibody that specifically binds an epitope of MUC1 and is capable of preventing tumor metastasis.
A method for reducing the growth kinetics of a solid tumor in a patient comprising the step of administering an IgE antibody specific for a tumor-associated antigen, wherein the antibody forms a ternary complex within the microenvironment of the tumor, said ternary complex being comprised of the IgE antibody, the tumor-associated antigen, and a host-derived non-tumor cell, wherein the antibody specifically binds to the tumor-associated antigen and an antibody receptor specific for IgE located on the surface of the non-tumor cell.
Dependencies are inferred from the claim text.